+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
HIV Clinical Trials Market - Global Forecast 2026-2032- Product Image
HIV Clinical Trials Market - Global Forecast 2026-2032- Product Image
Sale

HIV Clinical Trials Market - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5666075
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The HIV Clinical Trials Market is projected to reach USD 1.68 Billion in 2026. It is expected to continue growing at a CAGR of 5.65%, reaching USD 2.34 Billion by 2032.

HIV clinical trials are entering a decisive phase as global research priorities shift from incremental antiretroviral optimization toward long-acting prevention, broadly neutralizing antibodies, therapeutic vaccines, immune-based strategies, and potential cure-directed interventions. The clinical development landscape is shaped by the persistent public health burden of HIV, the need for more inclusive trial populations, and the growing demand for regimens that improve adherence, reduce stigma, and address drug resistance. According to international public health agencies, tens of millions of people are living with HIV globally, with prevention gaps, late diagnosis, and unequal access to treatment continuing to influence trial design and site selection. As a result, HIV clinical trials increasingly emphasize real-world feasibility, community engagement, pharmacokinetic diversity, pregnancy and adolescent inclusion, and representation of populations disproportionately affected by HIV, including men who have sex with men, transgender people, people who inject drugs, sex workers, and communities in high-incidence regions.

Transformative Shifts Reshaping HIV Clinical Trials

Transformative shifts in HIV clinical trials are being driven by scientific innovation, regulatory modernization, and a stronger focus on equity. Long-acting injectable and implantable prevention approaches have changed expectations for adherence-focused trial endpoints, while oral and injectable pre-exposure prophylaxis studies increasingly evaluate differentiated delivery models and population-specific acceptability. Cure research is expanding through latency-reversing agents, immune checkpoint modulation, gene editing concepts, stem-cell-based approaches, and combination immunotherapy strategies, although safety, durability, and scalability remain central challenges. Trial protocols are also evolving to include decentralized visits, remote monitoring, eConsent, mobile health adherence tools, and community-led recruitment, particularly where stigma and travel barriers limit participation. Regulators and ethics bodies are placing greater emphasis on participant protection, post-trial access, informed consent quality, and inclusion of pregnant and lactating people when scientifically justified. These shifts are transforming HIV clinical research from site-centered experimentation into more adaptive, participant-centered development programs.

Cumulative Impact of Artificial Intelligence on HIV Clinical Trials

Artificial intelligence is increasingly influencing HIV clinical trials by improving protocol design, participant identification, risk stratification, pharmacovigilance, and operational efficiency. Machine learning models can support analysis of epidemiological patterns, viral genetic diversity, resistance profiles, adherence behavior, and co-infection risks, helping investigators design more targeted and inclusive studies. Natural language processing can accelerate screening of electronic health records where permitted by privacy regulations, while predictive analytics can identify sites with stronger recruitment feasibility and retention potential. AI-enabled imaging, digital biomarkers, and wearable data streams may also contribute to safety monitoring and behavioral adherence assessment. However, the cumulative impact of AI depends on data quality, transparent validation, bias mitigation, cybersecurity, and compliance with clinical research regulations. In HIV clinical trials, where marginalized populations are often involved, responsible AI governance is essential to prevent algorithmic exclusion, protect confidentiality, and ensure that digital innovation strengthens rather than undermines trust.

Key Regional Insights Across Global HIV Clinical Trials

Asia-Pacific is becoming increasingly important for HIV clinical trials due to its demographic scale, diverse epidemic patterns, and expanding clinical research infrastructure, with China, India, Japan, South Korea, and Australia contributing distinct strengths across drug development, immunology, prevention, and regulatory science. Europe contributes strong multicountry trial coordination, pharmacovigilance systems, ethics oversight, and translational research capabilities, with emphasis on cohort science, resistance surveillance, differentiated care models, and harmonized clinical trial procedures. North America remains a major hub for early- and late-stage HIV studies supported by advanced trial networks, established regulatory pathways, extensive laboratory capacity, and strong experience in long-acting therapeutics, prevention studies, and cure-directed research. Latin America plays a growing role in prevention and treatment trials, particularly where urban HIV incidence, community health networks, and prior experience in infectious disease research support participant recruitment and real-world implementation studies. Africa remains central to global HIV clinical trials because it carries a substantial share of the global HIV burden and provides essential scientific insight into prevention, treatment optimization, maternal health, adolescent HIV, co-infections, and implementation strategies across high-incidence settings. The Middle East is seeing gradual expansion in clinical trial capacity, supported by investments in healthcare infrastructure and centralized specialist care, though stigma, diagnosis gaps, and cross-border regulatory variation affect recruitment.

Key Group Insights Influencing HIV Clinical Research

NATO member countries, many of which overlap with advanced research economies, contribute through biomedical security priorities, infectious disease preparedness, and clinical infrastructure that can support robust HIV trial conduct, especially where cross-border coordination and regulatory reliability are essential. G7 countries remain influential in HIV clinical research through advanced regulatory systems, laboratory capabilities, funding ecosystems, and experience with complex trial designs, including long-acting agents, immune therapies, and cure research. BRICS countries collectively bring large and diverse patient populations, expanding biomedical research capacity, and significant public health relevance, with Brazil, Russia, India, China, and South Africa contributing different insights into access, resistance, prevention uptake, co-infections, and implementation science. The European Union supports harmonized clinical trial regulation, cross-border ethics coordination, pharmacovigilance standards, and collaborative research networks that are particularly valuable for multicountry HIV treatment, prevention, and safety studies. ASEAN countries are increasingly relevant for HIV clinical trials because concentrated epidemics among key populations, expanding public health programs, and improving research governance create opportunities for prevention, diagnostics, and adherence-focused studies. The GCC region offers advanced healthcare infrastructure, growing clinical research investment, and centralized care models, but HIV-related stigma and smaller diagnosed patient pools require carefully designed recruitment strategies and confidentiality safeguards.

Key Country Insights for HIV Clinical Trial Development

China is expanding its role in HIV clinical trials through large-scale clinical infrastructure, biomedical innovation, and growing participation in antiviral research, while the United States is a leading environment due to its extensive academic trial networks, regulatory expertise, community advisory structures, and research focus on prevention, long-acting therapy, resistance, and cure strategies. Japan contributes advanced regulatory science, immunology research, and high-quality clinical operations, while India offers substantial scientific capacity, large patient populations, and experience in generics, diagnostics, and public health implementation. Germany, the United Kingdom, France, Italy, and Spain provide mature clinical research systems, specialist HIV centers, and multicountry European collaboration, with strong capabilities in pharmacovigilance, resistance monitoring, translational medicine, and cohort-based evidence generation. Australia is recognized for strong HIV prevention research, community engagement, and pragmatic trial design, while South Korea adds advanced hospital networks, digital health capability, and growing infectious disease research capacity, strengthening Asia-Pacific participation in global HIV clinical trials. Canada contributes strong cohort studies, public health integration, and expertise in key population research, while Russia remains relevant due to HIV epidemiology, co-infection concerns, and treatment access challenges, although regulatory and geopolitical factors can affect international trial participation. Brazil has long-standing HIV treatment infrastructure and research experience, making it important for prevention, treatment, and implementation studies in Latin America, while Mexico supports regional recruitment relevance through urban HIV care networks and cross-border public health considerations.

Actionable Recommendations for HIV Clinical Trial Leaders

Industry leaders should prioritize inclusive protocol design, scientifically justified enrollment of underrepresented populations, and early engagement with community advisory groups to improve trust, recruitment, and retention. Trial sponsors and investigators should align endpoints with real-world HIV care needs, including adherence, acceptability, resistance outcomes, drug-drug interactions, pregnancy safety, and durability of response. Decentralized trial tools should be deployed selectively, with strong safeguards for privacy, digital literacy, and participant confidentiality. Leaders should invest in regional site readiness, laboratory quality systems, staff training, and ethical review capacity, especially in high-burden regions where research participation must be matched with post-trial access planning. AI-enabled tools should be validated across diverse populations before operational use, and governance frameworks should address bias, explainability, cybersecurity, and compliance with data protection rules. Strategic partnerships with public health programs, community organizations, and regulatory stakeholders can improve feasibility while supporting trial designs that are scientifically rigorous, socially responsible, and operationally resilient.

Research Methodology for Evidence-Based HIV Clinical Trial Insights

This executive summary is developed through a structured secondary research approach using verified public health, regulatory, scientific, and clinical trial information sources. The methodology includes review of global HIV epidemiology from recognized public health agencies, analysis of clinical trial registry patterns, assessment of regulatory guidance on clinical research conduct, and synthesis of peer-reviewed literature related to antiretroviral development, HIV prevention, vaccine research, immune-based therapies, and cure-directed approaches. Regional, group, and country insights are interpreted through documented indicators such as disease burden, clinical research infrastructure, regulatory maturity, public health program capacity, and representation of key populations. The analysis excludes market sizing, market share, revenue estimation, and forecasting, focusing instead on evidence-based qualitative trends, scientific priorities, operational dynamics, and policy-relevant developments shaping HIV clinical trials.

Conclusion on the Future of HIV Clinical Trials

HIV clinical trials are advancing through a convergence of biomedical innovation, digital transformation, regulatory evolution, and stronger community-centered research practices. The field is moving beyond conventional treatment comparisons toward long-acting prevention, differentiated delivery, immunological interventions, and cure-oriented strategies that require sophisticated trial designs and diverse participant representation. Regional participation is broadening, with high-burden settings, advanced research economies, and emerging clinical research hubs each contributing essential evidence. Artificial intelligence and decentralized technologies can improve efficiency and precision, but their value depends on ethical governance, inclusivity, and validated performance across populations affected by HIV. The next phase of HIV clinical research will be defined by the ability of stakeholders to combine scientific rigor with equity, operational adaptability, and sustained commitment to participant trust and public health impact.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. HIV Clinical Trials Market, by Drug Class
7.1. Introduction
7.2. Entry Inhibitors
7.2.1. Enfuvirtide
7.2.2. Maraviroc
7.3. Integrase Strand Transfer Inhibitors
7.3.1. Bictegravir
7.3.2. Dolutegravir
7.3.3. Elvitegravir
7.3.4. Raltegravir
7.4. Non-Nucleoside Reverse Transcriptase Inhibitors
7.4.1. Efavirenz
7.4.2. Etravirine
7.4.3. Nevirapine
7.4.4. Rilpivirine
7.5. Nucleoside Reverse Transcriptase Inhibitors
7.5.1. Emtricitabine
7.5.2. Lamivudine
7.5.3. Tenofovir
7.5.4. Zidovudine
7.6. Protease Inhibitors
7.6.1. Atazanavir
7.6.2. Darunavir
7.6.3. Fosamprenavir
7.6.4. Lopinavir
8. HIV Clinical Trials Market, by Trial Phase
8.1. Introduction
8.2. Phase I
8.3. Phase II
8.3.1. Phase IIa
8.3.2. Phase IIb
8.4. Phase III
8.5. Phase IV
9. HIV Clinical Trials Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.3. Oral
9.4. Transdermal
10. HIV Clinical Trials Market, by Patient Age Group
10.1. Introduction
10.2. Adult
10.3. Geriatric
10.4. Pediatric
11. HIV Clinical Trials Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals
11.4. Research Institutes
11.4.1. Academic Institutes
11.4.2. Contract Research Organizations
12. HIV Clinical Trials Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.3. Online
13. HIV Clinical Trials Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. HIV Clinical Trials Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. HIV Clinical Trials Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. American Gene Technologies International Inc.
17.3. Assembly Biosciences, Inc.
17.4. BioNTech SE
17.5. Bristol-Myers Squibb Company
17.6. Charles River Laboratories International, Inc.
17.7. CytoDyn Inc.
17.8. Excision BioTherapeutics, Inc.
17.9. Frontier Biotechnologies Inc.
17.10. GeoVax Labs, Inc.
17.11. Gilead Sciences, Inc.
17.12. IAVI
17.13. ICON plc
17.14. International AIDS Vaccine Initiative, Inc.
17.15. IQVIA Holdings Inc.
17.16. Johnson & Johnson
17.17. Labcorp Drug Development Inc.
17.18. Medpace Holdings, Inc.
17.19. Merck & Co., Inc.
17.20. Moderna, Inc.
17.21. Novotech Health Holdings Pte. Ltd.
17.22. Parexel International Corporation
17.23. PPD, Inc.
17.24. Shanghai Henlius Biotech, Inc.
17.25. Syneos Health, Inc.
17.26. TaiMed Biologics Inc.
17.27. Theratechnologies Inc.
17.28. ViiV Healthcare Limited
17.29. Vir Biotechnology, Inc.
17.30. WuXi AppTec Co., Ltd.
List of Figures
FIGURE 1. GLOBAL HIV CLINICAL TRIALS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL HIV CLINICAL TRIALS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL HIV CLINICAL TRIALS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL HIV CLINICAL TRIALS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 13. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL HIV CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL HIV CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL HIV CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ENTRY INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ENTRY INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ENTRY INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ENFUVIRTIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ENFUVIRTIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ENFUVIRTIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL MARAVIROC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL MARAVIROC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL MARAVIROC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL INTEGRASE STRAND TRANSFER INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL INTEGRASE STRAND TRANSFER INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL INTEGRASE STRAND TRANSFER INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL BICTEGRAVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL BICTEGRAVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL BICTEGRAVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL DOLUTEGRAVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL DOLUTEGRAVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL DOLUTEGRAVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ELVITEGRAVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ELVITEGRAVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ELVITEGRAVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL RALTEGRAVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL RALTEGRAVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL RALTEGRAVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL EFAVIRENZ MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL EFAVIRENZ MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL EFAVIRENZ MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ETRAVIRINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ETRAVIRINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ETRAVIRINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL NEVIRAPINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL NEVIRAPINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL NEVIRAPINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL RILPIVIRINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL RILPIVIRINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL RILPIVIRINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL EMTRICITABINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL EMTRICITABINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL EMTRICITABINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL LAMIVUDINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL LAMIVUDINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL LAMIVUDINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL TENOFOVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL TENOFOVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL TENOFOVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ZIDOVUDINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ZIDOVUDINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ZIDOVUDINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ATAZANAVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ATAZANAVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ATAZANAVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL DARUNAVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL DARUNAVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL DARUNAVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL FOSAMPRENAVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL FOSAMPRENAVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL FOSAMPRENAVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL LOPINAVIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL LOPINAVIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL LOPINAVIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL PHASE I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL PHASE II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL PHASE IIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL PHASE IIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL PHASE IIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL PHASE IIB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL PHASE IIB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL PHASE IIB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL PHASE III MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL PHASE IV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL PHASE IV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL PHASE IV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL ACADEMIC INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL ACADEMIC INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL ACADEMIC INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2017-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 150. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 151. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 152. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 153. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 154. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 155. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 156. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 157. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2017-2032 (USD MILLION)
TABLE 158. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 159. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 160. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 161. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 162. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 163. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 164. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 165. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 166. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 167. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 168. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 169. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 170. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 171. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2017-2032 (USD MILLION)
TABLE 172. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 173. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 174. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 175. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 176. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 177. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 178. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 179. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 180. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 181. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 182. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 183. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 184. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 185. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2017-2032 (USD MILLION)
TABLE 186. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 187. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 188. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 189. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 190. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 191. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 192. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 193. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 194. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 195. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 196. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 197. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 198. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 199. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2017-2032 (USD MILLION)
TABLE 200. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 201. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 202. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 203. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 204. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 205. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 206. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 207. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 208. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 209. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 210. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 211. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 212. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 213. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2017-2032 (USD MILLION)
TABLE 214. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 215. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 216. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 217. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 218. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 219. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 220. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 221. NATO HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 222. NATO HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 223. NATO HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 224. NATO HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 225. NATO HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 226. NATO HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 227. NATO HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 228. NATO HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2017-2032 (USD MILLION)
TABLE 229. NATO HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 230. NATO HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 231. NATO HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 232. NATO HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 233. NATO HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 234. NATO HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 235. G7 HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 236. G7 HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 237. G7 HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 238. G7 HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 239. G7 HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 240. G7 HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 241. G7 HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 242. G7 HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2017-2032 (USD MILLION)
TABLE 243. G7 HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 244. G7 HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 245. G7 HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 246. G7 HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 247. G7 HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 248. G7 HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 249. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 250. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 251. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 252. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 253. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 254. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 255. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 256. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2017-2032 (USD MILLION)
TABLE 257. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 258. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 259. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 260. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 261. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 262. BRICS HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 270. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2017-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 273. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 274. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 275. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 276. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 277. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 278. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 279. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 280. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 281. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 282. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 283. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 284. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2017-2032 (USD MILLION)
TABLE 285. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 286. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 287. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 288. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 290. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 291. GCC HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 292. GCC HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 293. GCC HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 294. GCC HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 295. GCC HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 296. GCC HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 297. GCC HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 298. GCC HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2017-2032 (USD MILLION)
TABLE 299. GCC HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 300. GCC HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 301. GCC HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 302. GCC HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 303. GCC HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 304. GCC HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 305. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 306. CHINA HIV CLINICAL TRIALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 307. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 308. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 309. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 310. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 311. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 312. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 313. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2017-2032 (USD MILLION)
TABLE 314. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 315. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 316. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 317. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 318. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 319. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 320. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 321. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 322. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 323. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 324. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 325. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 326. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 327. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2017-2032 (USD MILLION)
TABLE 328. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 329. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 330. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 331. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 332. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 333. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 334. JAPAN HIV CLINICAL TRIALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 335. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 336. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 337. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 338. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 339. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 340. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 341. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2017-2032 (USD MILLION)
TABLE 342. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2017-2032 (USD MILLION)
TABLE 343. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 344. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 345. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 346. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2017-2032 (USD MILLION)
TABLE 347. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 348. INDIA HIV CLINICAL TRIALS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 349. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 350. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2017-2032 (USD MILLION)
TABLE 351. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2017-2032 (USD MILLION)
TABLE 352. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSI

Companies Mentioned

  • AbbVie Inc.
  • American Gene Technologies International Inc.
  • Assembly Biosciences, Inc.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Charles River Laboratories International, Inc.
  • CytoDyn Inc.
  • Excision BioTherapeutics, Inc.
  • Frontier Biotechnologies Inc.
  • GeoVax Labs, Inc.
  • Gilead Sciences, Inc.
  • IAVI
  • ICON plc
  • International AIDS Vaccine Initiative, Inc.
  • IQVIA Holdings Inc.
  • Johnson & Johnson
  • Labcorp Drug Development Inc.
  • Medpace Holdings, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novotech Health Holdings Pte. Ltd.
  • Parexel International Corporation
  • PPD, Inc.
  • Shanghai Henlius Biotech, Inc.
  • Syneos Health, Inc.
  • TaiMed Biologics Inc.
  • Theratechnologies Inc.
  • ViiV Healthcare Limited
  • Vir Biotechnology, Inc.
  • WuXi AppTec Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.68 Billion
Forecasted Market Value ( USD ) by 2032 $ 2.34 Billion
Compound Annual Growth Rate5.6%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

HIV Clinical Trials - Global Strategic Business Report - Product Image

HIV Clinical Trials - Global Strategic Business Report

  • Report
  • 379 Pages
  • Global
From
HIV Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

HIV Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 185 Pages
  • Global
From
Human Immunodeficiency Viruses (HIV) Clinical Trials Market Report 2026 - Product Image

Human Immunodeficiency Viruses (HIV) Clinical Trials Market Report 2026

  • Report
  • 250 Pages
  • Global
From
HIV Clinical Trials Market Outlook 2026-2034: Market Share and Growth Analysis - Product Image

HIV Clinical Trials Market Outlook 2026-2034: Market Share and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Human Immunodeficiency Virus Therapeutics Market - Global Forecast 2026-2032 - Product Image

Human Immunodeficiency Virus Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From

About the HIV Clinical Trial Market

The HIV Clinical Trial market is a subset of the larger Clinical Trials market, which focuses on the development of treatments and preventative measures for HIV/AIDS. HIV Clinical Trials are conducted to evaluate the safety and efficacy of new drugs, vaccines, and other treatments for HIV/AIDS. These trials are conducted in accordance with the ethical principles of the Declaration of Helsinki and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The HIV Clinical Trial market is highly regulated, with stringent requirements for the design, conduct, and reporting of clinical trials. The market is also subject to a variety of legal and ethical considerations, including patient privacy and informed consent. Companies in the HIV Clinical Trial market include Gilead Sciences, Merck, ViiV Healthcare, Janssen Pharmaceuticals, and GlaxoSmithKline. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.